Our Products

Our product is the world’s first approved microbiome-based therapy for the treatment of recurrent and refractory Clostridioides difficile infection.

Order now

An Overview

Our product is the first microbiome-based therapy approved as a biological in the world. The product is donor derived available in a frozen syringe-based formulation for colonoscopy and enema delivery. We are reformulating the product into a capsule and anticipate the encapsulated product to be available through hospitals and pharmacies in the near future.
The product is manufactured in a purpose built Australian GMP facility, following rigorous and quality-controlled screening, and manufacturing processes. It is currently supplied to hospitals and clinics throughout Australia and can be administered by healthcare professionals.

Read the Full Product Information Sheet

The Evidence

Donor derived Faecal Microbiota Transplantation (FMT) is  a highly effective therapy for the treatment of C.difficle infection; the most common cause of health care associated diarrhoea. Multiple randomised controlled trials and meta-analyses of these studies have demonstrated the superiority of FMT over antibiotic therapy alone for the treatment of recurrent C.difficile infection.

While FMT is now the standard of care for recurrent C.difficile infection in most international guidelines, evidence is emerging for its use in other diseases. BiomeBank’s co-founders Dr Sam Costello and Dr Rob Bryant have been pioneers in this field and BiomeBank is facilitating a number of clinical trials in a range of diseases with collaborating organisations.

Current Treatment (Antibiotics) vs Faecal Microbial Transplantation (FMT)


Antibiotic Treatment



Source: Faecal microbiota transplantation for recurrent clostridioides difficile infection: An updated systematic review and meta-analysis (The Lancet, Dec 2020)


To access further information or order our therapies please fill in your details below.